CorMedix (CRMD) Cost of Revenue (2013 - 2025)

CorMedix has disclosed Cost of Revenue across 13 years of filings, most recently posting $27.1 million for Q4 2025.

• Cost of Revenue for Q4 2025 came in at $27.1 million, up 1.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $49.2 million (up 17.7% YoY), and the FY2025 annual result was $38.1 million, up 32.42% from the prior year.
• Cost of Revenue came in at $27.1 million for Q4 2025 at CorMedix, up from $11.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $27.1 million in Q4 2025 to a low of $332.0 in Q2 2022.
• The 5-year median for Cost of Revenue is $3.3 million (2023), against an average of $5.6 million.
• Across the five-year window, Cost of Revenue sank 99.15% in 2022 and surged 2009668.97% in 2023, its largest moves.
• CorMedix's Cost of Revenue stood at $48007.0 in 2021, then tumbled by 99.15% to $406.0 in 2022, then soared by 2009668.97% to $8.2 million in 2023, then soared by 228.76% to $26.8 million in 2024, then advanced by 1.14% to $27.1 million in 2025.
• The last three Cost of Revenue figures came in at $27.1 million (Q4 2025), $11.2 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.